$Palisade Bio (PALI.US)$ BULLSHIT

$Palisade Bio (PALI.US)$ really trash

$Palisade Bio (PALI.US)$ trash stock 😂

$Palisade Bio (PALI.US)$ so many news but yet dont know fly

$Palisade Bio (PALI.US)$
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Thursday, 20th February at 8:45 am
Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108
Ongoing progress of Palisade Bio's Phase 1a/b UC st...

$Palisade Bio (PALI.US)$ Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Data presented at the 2025 Crohn's and Colitis Congress 
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts

$Palisade Bio (PALI.US)$
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Monday, 10th February at 8:45 am
Data presented at the 2025 Crohn's and Colitis Congress 
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Carlsbad, CA, Fe...

$Palisade Bio (PALI.US)$ This stock gave up already?

$Palisade Bio (PALI.US)$ When are you going to fly?

$Palisade Bio (PALI.US)$
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
Wednesday, 29th January at 8:45 am
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepte...